A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma (Q38992236)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Deepa K Krishnadas

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Suzanne Shusterman

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Fanqi Bai

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Lisa Diller

4

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Janice E Sullivan

5

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Alexandra C Cheerva

6

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Rani E George

7

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Kenneth G Lucas

8

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

24 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

64

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1251-1260

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Immune-based therapies for sarcoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Immunomic analysis of human sarcoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Membrane-associated phospholipase A1 beta (LIPI) Is an Ewing tumour-associated cancer/testis antigen.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

A simple estimate of glomerular filtration rate in adolescent boys.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Complete remission following decitabine/dendritic cell vaccine for relapsed neuroblastoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

CD137 as a biomarker for tumor-reactive T cells: finding gold in the desert.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

GM-CSF-dependent, CD103+ dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1731-3

21 January 2018

Identifiers

10.1007/S00262-015-1731-3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38992236&oldid=2202433572"